Putting patients first: how 金禾娱乐城 ensure that innovation in science meets real needs

Chiara Vona — Wed, 14 Dec 2022 11:06:14 +0000

Scott Fleming, Global Communications & Company Reputation

Chiara Vona Wed 14/12/2022 - 12:06

鈥業nnovation鈥� is a word we hear a lot in the pharmaceutical industry 鈥� be that innovative modes of action, innovative clinical development strategies or innovative digital solutions.

At 金禾娱乐城, we believe that innovation should always be linked to a patient insight. That can be an insight revealed through a greater understanding of disease biology, or it can be an insight captured through market research or translating their experiences, perspectives, and views into our clinical study design. That鈥檚 why we鈥檝e developed and implemented a new framework centred around our most important stakeholder 鈥� the patient. This new robust end-to-end framework is designed to ensure that patients and key stakeholders provide direct insight and input as early as possible into the overall strategy behind research and development programs, as well as the entire drug lifecycle. We believe this patient insight approach plays a vital role in achieving success for communities across the world, as we know true innovation is about designing solutions with patients, rather than simply designing medicines for them.

Traditionally, patients were viewed by pharmaceutical companies as simply consumers, but over the past decade, patients have been increasingly active and empowered when it comes to decisions concerning their health. Nowadays, they are considered true partners working towards a collective goal. Our framework takes into consideration this progression of the patient role, embracing the notion of patient centricity, which places importance on patients as 鈥榗o-creators鈥� in the R&D process. Patient engagement is no longer simply about validating assumptions or having patients participate in research; instead, it has become far more valuable to co-create solutions that tackle the diverse challenges that matter most to them as individuals and their caregivers.

When it comes to R&D, it鈥檚 critical to embed the 鈥榩atient鈥� early. By ensuring their needs are understood and embedded during the initial stages, research and development programs can be grounded in real-world insight, helping to inform more impactful decisions as the R&D journey continues. At 金禾娱乐城, we work to obtain a holistic and 360-degree data-enabled view of the patient, working in tandem to answer critical questions along the lifecycle of drug development. It provides an opportunity for patients to offer insights into unmet areas of need, on outcomes that matter most to them and potential areas of concern regarding study designs.

As an example, 金禾娱乐城 recently constructed the formulation, refinement and first evaluations of a new evidence-based approach to measure fatigue in Systemic Lupus Erythematosus (SLE), called FATIGUE- PRO (Patient Reported Outcomes) 鈥� developed in collaboration with patients who described their personal experience of living with the condition. These patients raised concerns that many instruments currently used to measure fatigue come with limitations, such as not addressing the breadth of fatigue they experience. The research team collected qualitative data throughout the process, and were able to refine the parameters, including physical fatigue, cognitive fatigue, and susceptibility to fatigue, based on patient insight. The result was a new PRO instrument to measure fatigue that addresses the conceptional limitations of current tools, and that will have a significant impact on the lives of SLE patients.

Listening and learning from patients at the earliest stages of research supports a deeper appreciation of patients鈥� reality and unmet needs. That鈥檚 what drives each and every one of us at 金禾娱乐城, though we鈥檙e all unique and all bring unique qualities to the work we do. That鈥檚 probably why we each have a unique take on what innovation means.

Find out more on why, at 金禾娱乐城, we鈥檙e driven to develop innovative solutions for patients here.

innovation

364 Likes

New patient-centred framework informs 金禾娱乐城鈥檚 approach to R&D drug development and ensures patients are at the heart of creating our innovative solutions

Vanco Vlastimil (金禾娱乐城 S.A.) — Mon, 21 Mar 2022 10:54:33 +0000

New patient-centred framework informs 金禾娱乐城鈥檚 approach to R&D drug development and ensures patients are at the heart of creating our innovative solutions

Becky Malone, Patient Value Development Solutions

Vanco Vlastimi鈥� Mon 21/03/2022 - 11:54

As part of its commitment to create innovative solutions and transform the lives of people living with severe diseases, 金禾娱乐城 has developed and implemented a new framework centred around its most important stakeholder 鈥� the patient. 金禾娱乐城鈥檚 new robust end-to-end framework, designed to ensure that patients and key stakeholders provide direct input as early as possible into the overall strategy behind research and development programs, as well as the entire drug lifecycle, will play a vital role in achieving successful outcomes for patient communities in the future.

Over the last decade, patients have been increasingly active and empowered when it comes to decisions concerning their health. Traditionally patients were viewed by pharmaceutical companies as simply customers, nowadays they are considered true partners working towards a collective goal. As a result of this patient role progression, the pharmaceutical industry has embraced the notion of patient centricity, which places importance on patients as 鈥榗o-creators鈥� in the R&D process.

Patient engagement is no longer simply about validating assumptions or having patients participate in research; instead, it has become far more valuable to co-create solutions that tackle the diverse challenges that matter most to them as individuals and their caregivers.

Critical to 金禾娱乐城鈥檚 patient-centred framework is inclusion of the patient voice early in the R&D process, ensuring their needs are understood and embedded early in the research to help inform decisions. It is a vital part of gaining a holistic and 360-degree data-enabled view of the patient and involves working together to answer critical questions along the lifecycle of drug development.

This adds tremendous value by ensuring that patient perspectives form the basis of future operations and outcomes. In tandem, it provides an opportunity for patients to offer insights into unmet areas of need, on outcomes that matter most to them and potential areas of concern regarding study designs.

As an example, 金禾娱乐城 recently constructed the formulation, refinement and first evaluations of a new evidence-based approach to measure fatigue in Systemic Lupus Erythematosus (SLE), called FATIGUE- PRO (Patient Reported Outcomes) 鈥� developed in tandem with patients who described their direct and explicit experiences of living with the condition.

金禾娱乐城 understood patients鈥� concerns that many instruments currently used to measure fatigue come with limitations such as not addressing the breadth of fatigue experienced by those living with the condition. The research team collected qualitative data throughout the process, refining the parameters, including physical fatigue, cognitive fatigue and susceptibility to fatigue, based on patient evidence. The final outcome was a new PRO instrument to measure fatigue that addresses the conceptional limitations of current tools, and that will have a significant impact on the lives of SLE patients.

The new patient-centred framework supports 金禾娱乐城鈥檚 scientists as they look to advance their understanding of human and disease biology. Listening and learning from patients at the earliest stages of research support a deeper appreciation of patients鈥� reality and unmet needs, allowing them to turn science into meaningful solutions that will transform the way diseases are treated.

In another recent instance of patient co-creation, 金禾娱乐城 engaged with a Think Tank to ensure the patient voice was accurately reflected in their benefit risk assessments. By receiving this insight first-hand in a collaborative environment, 金禾娱乐城 can better determine the risks and benefits of a treatment, leading to improved outcomes for patients down the line.

It鈥檚 clear that patients are at the heart of everything 金禾娱乐城 does, and along with the pharmaceutical industry, as a whole, is embracing the role of patients as agents in their own healthcare journey. By partnering with patients in a specially designed patient-centric framework, and thus providing patients a more meaningful experience and role as co-creators, more impactful patient outcomes are on the horizon.

solutions

Patients R&D patient centricity SLE FATIGUE-PRO

587 Likes

FATIGUE-PRO

Putting patients first: how 金禾娱乐城 ensure that innovation in science meets real needs

Leave a Comment

New patient-centred framework informs 金禾娱乐城鈥檚 approach to R&D drug development and ensures patients are at the heart of creating our innovative solutions

Leave a Comment